Search results | pfizer


Partnering Agreements with Pfizer

This report provides all the information you require to better understand Pfizer and its partnering interests and activities over the past seven years.


More merger talks for Claris Lifesciences: Pfizer, Amneal, Novartis…

India-based CLARIS Lifesciences Ltd., which operates a generic sterile injectables business, has become the belle of the ball as multi-national companies such as Pfizer Inc., Amneal, Novartis AG and Indian companies such as Lupin and Cipla, are lining up to play the

Pfizer is in talks to acquire Actavis

Pfizer Inc. has approached Actavis with a possibility to acquire the company.

AstraZeneca and Pfizer in the news for another possible m&a bid

AstraZeneca stock rose two percent to £45.67 pounds yesterday after the Swedish newspaper Dagens Industry suggested another possible Pfizer m&a  bid. AstraZeneca stocks have risen 9.5% in the last week, following a stream of good news regarding its pipeline and takeover bids by Pfizer.

Is Pfizer’s next acquisition target, Actavis?

Bloomberg reports, Pfizer is looking at Actavis, the generics maker with a new home address in Ireland, among other targets.

Pfizer gives up on AstraZeneca

Pfizer has given up on its attempt to take over the British pharmaceutical company AstraZeneca.


Pfizer is a top pharmaceutical company based in New York, USA

AstraZeneca rejects Pfizer’s final offer, again

On Friday May 16th, 2014, Pfizer announces its final proposal to combine the two companies.

AstraZeneca rejects Pfizer’s takeover offer

The board of pharmaceutical company AstraZeneca on Friday flatly rejected drug maker Pfizer’s sweetened takeover offer just hours after it was levelled, describing it as inadequate.

Pfizer confirms its offer for AstraZeneca

Pfizer is close to publicly unveiling its interest in acquiring AstraZeneca of Britain, a person briefed on the matter said on Sunday, in what would be one of the biggest deals among drug makers.

Rumours swirl of Pfizer bid for AstraZeneca triggering M&A fever

The recently disclosed failed bid by Pfizer to acquire bigpharma rival AstraZeneca has analysts predicting several outcomes as M&A fever sweeps the pharma sector


Sorry, your search returned no results.


Pfizer creates breaking news with Allergan purchase

US drugs giant Pfizer has sealed a deal to buy Botox-maker Allergan for $160bn (£106bn) in what is the biggest pharmaceuticals deal in history.

Pfizer in asset purchase and option to acquire AM-Pharma

Pfizer has acquired a minority equity interest in AM-Pharma and secured an exclusive option to acquire the remaining equity in the company.

EMD Serono and Pfizer in co-promotion agreement for Xalkori

EMD Serono has begun co-promoting Pfizer’s anaplastic lymphoma kinase (ALK) inhibitor XALKORI (crizotinib) as part of its global strategic alliance with Pfizer.

Pfizer in collaboration agreement for lupus study

23andMe announced the launch of the Lupus Research Study in collaboration with Pfizer.

Pfizer and ADDF in Alzheimer’s disease pact

The Alzheimer’s Drug Discovery Foundation (ADDF) and Pfizer’s Centers for Therapeutic Innovation (CTI) announced a collaboration designed to advance the development of new small-molecule drugs for Alzheimer’s disease and related dementias

Pfizer enters into $17bn merger agreement with Hospira

Pfizer and Hospira have entered into a definitive merger agreement under which Pfizer will acquire Hospira, the world’s leading provider of injectable drugs and infusion technologies and a global leader in biosimilars,

Pfizer terminates spinal muscular atrophy pact with Repligen

Pfizer issued to Repligen a notice of termination for convenience under the License Agreement, dated December 28, 2012

Pfizer and HemoShear to develop predictive model for preclinical drug-induced vascular injury

HemoShear announced a multi-year platform collaboration with Pfizer

Pfizer acquires Redvax, gains promising CMV vaccine candidate

Pfizer has acquired a controlling interest in Redvax

Philogen agrees pharma licensing deal with Pfizer for ADC’s

Philogen entered into a pharma licensing agreement with Pfizer to develop and commercialize empowered antibodies.